Wir sind mit live! Mehr erfahren
QSI-Symbol

Quantum-Si Incorporated

1,12 USD
-0,19
14,5 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
1,11
-0,01
0,89 %
1 Tag
-14,5 %
5 Tage
-24,32 %
1 Monat
53,4 %
3 Monate
36,7 %
6 Monate
7,69 %
Seit Jahresbeginn
-3,45 %
1 Jahr
-55,91 %
5 Jahre
-86,31 %
10 Jahre
-88,66 %
 

Profil: Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

Mitarbeiter: 145

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 81,3 %
Negativ 18,8 %
Neutral
GlobeNewsWire
vor 17 Stunden
Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026.
Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
Neutral
GlobeNewsWire
gestern
Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).
Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
Seeking Alpha
vor 5 Tagen
Leading Indicators For The October Breakout Cycle
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
Leading Indicators For The October Breakout Cycle
Negativ
InvestorPlace
vor 7 Tagen
Beyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Race
Elon Musk's Neuralink is giving us a glimpse of a future in which the human brain can communicate directly with computers. For investors, there's just one problem: You can't buy Neuralink stock.
Beyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Race
Neutral
GlobeNewsWire
vor 8 Tagen
Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
BRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated detection of 19 amino acids in its Proteus™ development program and is now working to deploy that capability into a developmental sequencing kit for routine use on integrated Proteus instruments.
Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
Negativ
Benzinga
vor 11 Tagen
Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Collapse In Q4
Neutral
Schaeffers Research
vor 15 Tagen
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
3 Biotech Stocks Put Traders Are Targeting Today
Neutral
GlobeNewsWire
vor 18 Tagen
Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument.
Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
Neutral
GlobeNewsWire
letzten Monat
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments.
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
Neutral
GlobeNewsWire
letzten Monat
Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities
BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing.
Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities
Kursdiagramme mit Lightweight Charts™ umgesetzt